⌘K

Login Start Free

Home/Filings/4/0000899243-20-012297

4//SEC Filing

HOLMLUND JON T 4

Accession 0000899243-20-012297

CIK 0001563577other

View on SEC.gov Company Profile

Filed

May 6, 8:00 PM ET

Accepted

May 7, 7:12 PM ET

Size

20.1 KB

Accession

0000899243-20-012297

Insider Transaction Report

Form 4

Period: 2020-05-05

Galera Therapeutics, Inc.GRTX

Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option
2020-05-06−1,489→ 15,856 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (1,489 underlying)
Exercise/Conversion
Stock Option
2020-05-07−2,059→ 13,797 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (2,059 underlying)
Exercise/Conversion
Stock Option
2020-05-05−3,064→ 17,345 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (3,064 underlying)
Exercise/Conversion
Common Stock
2020-05-05$1.07/sh+3,064$3,278→ 3,064 total
Sale
Common Stock
2020-05-05$12.16/sh−3,064$37,258→ 0 total
Exercise/Conversion
Common Stock
2020-05-06$1.07/sh+1,489$1,593→ 1,489 total
Sale
Common Stock
2020-05-06$12.00/sh−1,489$17,868→ 0 total
Exercise/Conversion
Common Stock
2020-05-07$1.07/sh+2,059$2,203→ 2,059 total
Sale
Common Stock
2020-05-07$12.00/sh−2,059$24,709→ 0 total

Footnotes (4)

[F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2019.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The option has fully vested and is currently exercisable.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Galera Therapeutics, Inc.

CIK 0001563577

Entity typeother

IncorporatedDE

Related Parties

1

filerCIK 0001227367

Filing Metadata

Form type: 4
Filed: May 6, 8:00 PM ET
Accepted: May 7, 7:12 PM ET
Size: 20.1 KB

View on SEC.gov